Data demonstrate benefits of nurse-led programme on patient self-management of RA

Jun 14 2013

Positive impact on physician prescribing and disease co-morbidities

Data first presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism demonstrate the benefits of a nurse-led programme on patient self-management and the management of rheumatoid arthritis (RA) co-morbidities.

The COMEDRA study was a six-month trial involving patients with RA who attended one of the twenty participating treatment centres in France. Patients were randomly allocated to one of two arms of the trial; the evaluation of nurse-led programmes on patient self-assessment or on the management of co-morbidities.

Within six months the patient self-assessment arm showed 89% of patients completed self-assessment and calculated their Disease Activity Score (DAS). The results were shared with their treating rheumatologist, which resulted in 17.2% changing their drug therapy (p=0.0012). Regular assessment of disease activity enables measurement of disease status over time (e.g. flares); while unfeasible in the clinic these data show that it can be undertaken by nurses and patients.

RA patients are at increased risk of associated diseases such as cardiovascular disease (CVD) or infections. In the arm where a nurse-led programme assessed potential co-morbidities and risk factors, at 6 months the number of actions taken to reduce co-morbidities, per patient, was significantly higher (p<0.001). The action taken into account varied depending on the co-morbidity, for example patients with CVD might have had lipid-lowering or anti-platelet therapies introduced, whereas those with an infection risk may have been vaccinated.

RA is a chronic autoimmune disease that principally attacks flexible joints. Affecting approximately 1 in 100 people worldwide, RA can cause pain, stiffness, progressive joint destruction and also reduce physical function, quality of life and life expectancy. In addition, RA is associated with a number of co-morbidities, including cardiovascular disease, cancer, lung disease, gastrointestinal disorders and infection.

Prof. Maxime Dougados, Professor of Rheumatology at Ren- Descartes University, Chief of Rheumatology at Cochin Hospital, Paris, France, and a principal investigator on the study said, "Treat to Target and EULAR recommendations suggest that we should be promoting self-management skills so that patients can regularly assess their own disease activity. Nurses can participate in this teaching. Looking at this data the positive impact of a nurse-led programme is clear; not only did the majority of patients participate in self-assessment, but within just six months the assessments resulted in many patients actually changing treatment."

Commenting on the impact of nurse intervention on comorbidities, Dr. Gossec, Associate Professor of Rheumatology in Paris 6 University and Pitie-Salpetriere Hospital, Paris, France, said "Patients with RA are at an increased risk of developing a number of co-morbid conditions which have a major influence on both mortality and disease outcome. During this trial, the number of actions undertaken to prevent these co-morbidities was significantly greater in the arm where nurses had thoroughly assessed the risks, with particular improvements observed against cardiovascular disease, infections, cancer and osteoporosis."

Patients in the self-assessment arm were asked to self-measure their inflamed joints and report results of DAS28-ESR. In the co-morbidities arm, the number of actions undertaken according to the recommendations was measured; actions taken into account included the introduction of lipid-lowering therapy, smoking cessation, weight loss, vaccinations and consultation with oncology specialists.

"These data demonstrate that in the short term, nurse-led interventions can equip patients with the tools required to more effectively manage their disease. Longer-term patient follow up is required to investigate the sustainability of these benefits, but these data have the potential to significantly alter the management of RA," concluded Prof. Dougados.

Source: European League Against Rheumatism